MedTrace Logo

Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

NCT05847764 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2023-05-08

No results posted yet for this study

Summary

Disitamab Vedotin combined therapy locally advanced or metastatic NSCLC Patients with HER2 Alterations.

Conditions

  • Non Small Cell Lung Cancer
  • ERBB2 Mutation-Related Tumors
  • RC48
  • Disitamab Vedotin

Interventions

DRUG

RC48+Tislelizumab+carboplatin

RC48+PD-1/PD-L1 inhibitor+chemo in treatment-naive patients harboring HER2 alterations

DRUG

RC48+Furmonertinib, 1L

RC48+Furmonertinib in treatment-naive patients harboring EGFR mutations as well as HER2 alterations

DRUG

RC48+Furmonertinib, 2L+

RC48+Furmonertinib in patients who failed at least one line of standard treatment and harboring HER2 alterations

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Li PI Zhang, MD · Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-31
Primary Completion
2024-10-31
Completion
2025-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05847764 on ClinicalTrials.gov